

Curative approach to peritoneal metastases from colorectal cancer is supported by evidence based medicine

Paul H. Sugarbaker

The benefits that are reported in patients that have carcinomatosis from colorectal cancer increase as the extent of disease within the abdomen and pelvis decreases. To optimize treatments that use cytoreductive surgery (CRS) and perioperative chemotherapy, early intervention is necessary. Strategies to improve the results of carcinomatosis treatments include second-look surgery and perioperative chemotherapy shortly after a short course of neoadjuvant 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX) chemotherapy in patients at high risk for recurrence. Alternatively, the use of hyperthermic intraperitoneal chemotherapy (HIPEC) can be used to treat or prevent carcinomatosis at the time of primary colorectal cancer resection in selected patients.

*Todos los derechos de propiedad intelectual son del autor. Queda prohibida la reproducción total o parcial de la obra sin autorización expresa del autor.

© FUNDACIÓN RAMÓN ARECES. Todos los derechos reservados.

**All intellectual property rights belong to the author. Total or partial reproduction of the work without express permission of the author is forbidden.*

© FUNDACIÓN RAMÓN ARECES. All rights reserved.